美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Rifampin	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Rifamycin Sodium	Tablet (Delayed Release)	II (Paddle)	100	Acid stage: HCl 0.1 N with 0.5% w/v Macrogol Cetostearyl Ether; Buffer stage: pH 7.2 Sodium Phosphate buffer		Acid Stage: 2 hours; Buffer Stage: 1, 2, 3 and 4 hours	2021/04/22
Rifapentine	Tablet	II (Paddle)	50	0.8% SLS in Phosphate Buffer, pH 7.0	900	10, 20, 30, 45, 60 and 90	2004/02/25
Rifaximin (200 mg)	Tablet	II (Paddle)	75	0.1M sodium phosphate buffer pH 7.4 containing 0.45% Sodium Lauryl Sulfate	1000	10, 20, 30, 45, 60, 90 and 120	2011/07/21
Rifaximin (550 mg)	Tablet	II (Paddle)	75	0.1M sodium phosphate buffer pH 7.4 containing 0.8% Sodium Lauryl Sulfate	1000	10, 20, 30, 45, 60, 90 and 120	2011/07/21
Rilpivirine HCl	Tablet	II (Paddle)	75	0.5% Polysorbate 20 in 0.01N HCl (pH=2.0)	900	10, 20, 30, 45 and 60	2013/08/15
Riluzole	Suspension	II (Paddle)	35	Phosphate Buffer pH 4.5	900 [890 mL of medium + 10 mL of suspension]	5, 10, 20, 30, 45 and 60	2022/05/12
Riluzole	Tablet	II (Paddle)	50	0.1 N HCl	900	10, 20, 30, 45 and 60	2004/02/18
Rimantadine HCl	Tablet			Develop a dissolution method			2023/09/15
Rimegepant Sulfate	Tablet, (Orally Disintegrating (ODT))	II (Paddle)	50	50 mM Sodium Acetate Buffer, pH 4.5	500	5, 10, 15, 20 and 30	2022/05/12
Rimexolone	Ophthalmic Suspension			Develop a method to characterize in vitro release			2016/06/30
Riociguat	Tablet	II (Paddle)	75	pH 6.8 Phosphate Buffer with 0.1% Sodium Lauryl Sulfate [SLS]	900	5, 10, 15, 20 and 30	2015/12/24
Ripretinib	Tablet	II (Paddle)	75	10 mM Sodium Acetate Buffer, pH 4.5, containing 0.25% (w/v) sodium dodecyl sulfate (SDS)	900	5, 10, 15, 20, 30 and 45	2022/05/12
Risedronate Sodium	Tablet			Develop a dissolution method			2024/01/03
Risedronate Sodium	Tablet (Delayed Release)	II (Paddle)	75	Acid stage: 0.1 N HCl; Buffer stage: Phosphate buffer, pH 6.8	Acid stage: 500; Buffer stage: 500	Acid stage: 120; Buffer Stage: 10, 15, 20, 30 and 45	2012/01/26
Risedronate Sodium/Calcium Carbonate	Tablet (Copackaged)			For Risedronate Tablets: Refer to USP; For Calcium Carbonate Tablets: Refer to USP.			2010/07/01
Risperidone	Injectable			Develop a dissolution method using USP IV (Flow-Through Cell), and, if applicable, Apparatus II (Paddle) or any other appropriate method, for comparative evaluation by the Agency			2010/01/15
Risperidone	Tablet	II (Paddle)	50	0.1 N HCl	500	10, 20, 30, 45 and 60	2006/03/04
Risperidone	Tablet (Orally Disintegrating)	II (Paddle)	50	0.1 N HCl	500	5, 10, 15	2004/07/23
Risperidone	For Suspension (Extended Release)	IV (Flow thru cell-closed loop)		50 mM Potassium Phosphate Buffer, pH 7.4	1000	8, 24, 96, 120, 144, 168, 192, 216 and 264 hours	2025/06/23